MarketCapExport financials
ADiTx Therapeutics (ADTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ADiTx Therapeutics Balance Sheet 2025-2011 | ADTX
Brief overview of ADiTx Therapeutics's financial position
The review uses the five latest available annual reports between 2021 and 2025.
The asset base was stable: the change from $16.7 million to $16.5 million does not indicate a material increase in scale.
Asset growth of -0.9% came with a +93.8% rise in liabilities. Financial leverage became more prominent.
Shareholders' equity accounts for 34% of assets, previously 61.1%. Dependence on liabilities is moderate.
Net debt moved below zero to -$2.4 million, reflecting surplus cash over debt.
Cash equals 19.4% of the balance sheet, compared with 47.2% five periods ago. This is the readily available cushion.
The accumulated result is -$209.8 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
What the balance sheet shows
ADiTx Therapeutics's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet ADiTx Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-2.36 M | 287 K | 1.94 M | 203 K | - | -8.66 M | 162 K | 47.9 K | -25 K | - | - | - | - | - | - |
Long Term Debt |
34.2 K | 436 K | 1.04 M | 1.89 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
808 K | 683 K | 1 M | 1.09 M | - | 391 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 858 K | - | - | 25 K | - | - | - | - | - | - |
Total Current Liabilities |
12.2 M | 23.4 M | 25.9 M | 3.64 M | 3.61 M | 1.23 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
12.6 M | 23.9 M | 28.5 M | 5.53 M | 6.48 M | 2.09 M | 2.98 M | 1.65 M | 84.9 K | - | - | - | - | - | - |
Retained Earnings |
-210 M | -168 M | -128 M | -95 M | -67.4 M | -20.9 M | -11.7 M | -5.9 M | -213 K | - | - | - | - | - | - |
Total Assets |
16.5 M | 32.1 M | 44.6 M | 10.7 M | 16.7 M | 13.1 M | 124 K | 116 K | 25 K | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.2 M | 833 K | 97.1 K | 2.77 M | 7.87 M | 10.5 M | 4.09 K | - | - | - | - | - | - | - | - |
Book Value |
3.95 M | 8.29 M | 16 M | 5.21 M | 10.2 M | 11 M | -2.85 M | -1.54 M | -59.9 K | - | - | - | - | - | - |
Total Shareholders Equity |
5.61 M | 1.67 M | 16.1 M | 5.21 M | 10.2 M | 11 M | -2.85 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet ADiTx Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
289 K | 436 K | 113 K | 277 K | 436 K | 592 K | 745 K | 892 K | 1.04 M | 1.2 M | 1.42 M | - | 1.89 M | - | - | - | 5 | 2.77 M | 2.96 M | 779 K | 858 K | 865 K | 858 K | 858 K | - | - | - | - | - | - | - | 35 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
49.1 M | 20.7 M | 20.7 M | 15.5 M | 23.9 M | 25.4 M | 22 M | 18.2 M | 28.5 M | 12.4 M | 11.2 M | 7.57 M | 5.53 M | 6.49 M | 9.38 M | 7.07 M | 6.48 M | 6.61 M | 9.94 M | 6.65 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 2.98 M | 2.98 M | 2.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-226 M | -205 M | -181 M | -174 M | -168 M | -163 M | -150 M | -142 M | -128 M | -117 M | -107 M | -101 M | -95 M | -86.8 M | -79.3 M | -73.4 M | -67.4 M | -43.3 M | -33.4 M | -27.3 M | -20.9 M | -20.9 M | -20.9 M | -20.9 M | -11.7 M | -11.7 M | -11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
13.9 M | 11.8 M | 32.7 M | 31.2 M | 32.1 M | 29.8 M | 28.4 M | 28 M | 44.6 M | 8.23 M | 7.29 M | 7.63 M | 10.7 M | 19.2 M | 10.7 M | 11.8 M | 16.7 M | 19.6 M | 15.9 M | 18 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 124 K | 124 K | 124 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
269 K | 163 K | 324 K | 476 K | 833 K | 329 K | 91.2 K | 88.7 K | 97.1 K | 1.65 M | 96 K | 303 K | 2.77 M | 9.24 M | 804 K | 2.12 M | 7.87 M | 5.47 M | 8.61 M | 14 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 4.09 K | 4.09 K | 4.09 K | - | 116 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-35.2 M | -8.86 M | 12 M | 15.8 M | 8.29 M | 4.45 M | 6.34 M | 9.78 M | 16 M | -4.22 M | -3.87 M | 68.1 K | 5.21 M | 12.7 M | 1.36 M | 4.72 M | 10.2 M | 13 M | 5.96 M | 11.4 M | 11 M | 11 M | 11 M | 11 M | -2.85 M | -2.85 M | -2.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-33.3 M | -7.73 M | 13 M | 16.6 M | 497 K | 4.71 M | 6.34 M | 9.78 M | 16.1 M | -4.22 M | -3.87 M | 68.1 K | 5.21 M | 12.7 M | 1.36 M | 4.72 M | 10.2 M | 13 M | 5.96 M | 11.4 M | 11 M | 11 M | 11 M | 11 M | -2.85 M | -2.85 M | -2.85 M | -1.81 M | -1.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of ADiTx Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
